Histological Investigation of Methacrylate Embedded Bone Marrow Biopsy Specimens; Correlation With Survival After Conventional Treatment in 15 Adult Patients

Velde, J. te; Haak, H. L.

doi:10.1111/j.1365-2141.1977.tb00563.x

Cited by 57 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Methyl methacrylate (MMA) has been used with great success for routine undecalcified bone histology for nearly forty years (Schenk 1965, Burkhardt, 1966Te Velde, 1977). However, enzyme-and immunohistochemistry in MMA embedded sections remains difficult and thus without wide-spread acceptance.…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemistry of matrix markers in Technovit 9100 New®-embedded undecalcified bone sections

Yang¹,

Davies²,

Archer³

et al. 2003

eCM

View full text Add to dashboard Cite

Trabecular bone is routinely analysed by histomorphological-histometrical and immunohistochemical techniques as means of assessing the differentiation status of bone deposition and growth. Currently few embedding resins exist for which both morphological and immunohistochemical analyses can be performed on mineralised tissue. Paraffin, the standard embedding medium for bone enzyme and immunohistochemistry, can only be used on demineralised tissue, but then trabecular structure may be badly preserved. Methyl methacrylate (MMA), the resin of choice for undecalcified bone histology can only be used for bone immunohistochemistry if the usual, highly exothermic polymerisation procedure is avoided which destroys both, enzyme activity and tissue antigenicity. Consequently, most current practices involve cutting samples in half to be processed in separate embedding media when more than one type of analysis is required. Technovit 9100 New® is a low temperature MMA embedding system that is purported to significantly improve tissue antigenicity preservation allowing polymerisation at -20°C. In this study, Technovit 9100 New®-embedded undecalcified trabecular bone samples (adult human, young bovine and ovine) yielded immunolabelling with several bone matrix markers and preserved morphological features in 7µm sections when stained with Masson-Goldner, von Kossa, or toluidine blue. Bone samples from all resins used (routine MMA, LR White, Technovit 9100 New®) were immunolabelled with antibodies against osteocalcin, alkaline phosphatase, osteopontin, osteonectin, bone sialoprotein and procollagen type I amino-terminal propeptide. Technovit 9100 New® -embedded bone yielded more reliable immunolabelling of the matrix proteins when compared with heat or cold-cured LR White or standard embedded MMA samples. Technovit 9100 New® provided better routine histology than LR White, and was comparable to MMA. Results demonstrated that Technovit 9100 New® can be used as a low-temperature acrylic resin embedding method for routine undecalcified bone histology, as well as for immunohistochemistry.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunohistochemistry of matrix markers in Technovit 9100 New®-embedded undecalcified bone sections

Yang¹,

Davies²,

Archer³

et al. 2003

eCM

View full text Add to dashboard Cite

show abstract

“…En los últimos años se esta tratando de encontrar parámetros de respuesta a la terapia inmunosupresora en la biopsia de hueso de los pacientes con AAS (40) (51) (52). TeVeld y Haak (52) propusieron que el grado de infiltrado inflamatorio en la médula ósea puede ser mayor en algunos casos con respuesta inmune activa; lo que sugeriría que un alto grado de infiltrado inflamatorio pudiera predecir una respuesta favorable a la terapia inmunosupresora en pacientes con AAS.…”

Section: Discussionunclassified

Aplasia medular

ULLOA¹,

MUSAYON²

2013

Rev Med Hered

View full text Add to dashboard Cite

SUMMARYFifty four patients with aplastic Anemia were studied from Jan 1983 to Jun 1992 at the Hospital Nacional Cayetano Heredia. Complete information was obtained in 51 cases. Thirty two (62.7%) were male and nineteen (37.3%), female. Mean age was 25 years old; 51% was under 20 years old. Thirty two patients (62.7%) had history of probably causal agent in the last year before diagnosis. The incidence was 4.05 cases/100,000 out patients and 4.8 cases/10,000 discharged patients in our hospital. Severe aplastic anemia (SAA) was observed in 83.7% of the cases, non severe anemia aplastic (NSAA) in 16.3% and 10% of the patients had very severe Aplastic Anemia (VSAA). Sixteen patients were treated with high doses of 6-metil-prednisolona (6-MP), four patients received antilymphocyte globuline and thirty one patients androgens and support therapy. Sepsis was the mortality cause in 50% of cases, bleeding in Central Nervous System 42.9% and in 7.1% sepsis and bleeding were the cause of death. The mean survival probability was higher in the group treated with high doses of 6-MP than in the patients treated with androgens and support only. (Rev Med Hered 1993; 4(3): 106-114)

show abstract

“…The value of the Lynch-and also Najean-index was as sessed by several authors in recent years. Wehinger and Lencer [1977] found the Lynch-index valuable for identification of high-risk cases dying within 6 months af ter diagnosis, whereas Te Velde and Haak [1977] judged the Lynch-index to have no more predictive value than the clinical im pression. According to Sleijjeret al [1981] the Lynch-as well as the Najean-index are less reliable than the prognostic systems of Camitta et al [1975] and Lohrmann et al [ 1976].…”

Section: Discussionmentioning

confidence: 99%

Prognosis in Acquired Aplastic Anemia

et al. 1984

View full text Add to dashboard Cite

To study prognostic factors 38 consecutive patients with aplastic anemia were evaluated until death or over a follow-up period of at least 4 years. A prognostic formula was devised by multivariate analysis for prediction of short-term survivors at diagnosis of aplastic anemia: Using the initial percentage of nonmyeloid cells in the marrow aspirate and the neutrophil count in peripheral blood, survival of less than 4 months is predicted with a probability of 89% (sensitivity 80%). The lowest blood counts during the course of the disease are useful to predict the outcome in more chronic courses of aplastic anemia: A reticulocytopenia below 5 × 10⁹/1, a neutropenia below 0.1 × 10⁹/1 or a thrombocytopenia below 5 × 10⁹/1 all resulted in an ultimate mortality of over 90%. However, if none of these threshold values were reached, a 4 year survival of 71 % was observed. Thus, 5× 10⁹ reticulocytes/1, 0.1 × 10⁹ neutrophils/1 and 5× 10⁹ platelets/1 form a group of risk factors to predict a fatal or favorable outcome throughout the course of the disease.

show abstract

Histological Investigation of Methacrylate Embedded Bone Marrow Biopsy Specimens; Correlation With Survival After Conventional Treatment in 15 Adult Patients

Cited by 57 publications

References 24 publications

Immunohistochemistry of matrix markers in Technovit 9100 New®-embedded undecalcified bone sections

Immunohistochemistry of matrix markers in Technovit 9100 New®-embedded undecalcified bone sections

Aplasia medular

Prognosis in Acquired Aplastic Anemia

Contact Info

Product

Resources

About